Skip Navigation


European Heart Journal Advance Access originally published online on November 16, 2005
European Heart Journal 2006 27(1):10-12; doi:10.1093/eurheartj/ehi653
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
27/1/10    most recent
ehi653v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Rauchhaus, M.
Right arrow Articles by Anker, S. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rauchhaus, M.
Right arrow Articles by Anker, S. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Heart failure therapy: testosterone replacement and its implications

Mathias Rauchhaus1,*, Wolfram Doehner1 and Stefan D. Anker1,2

1Abteilung für Angewandte Kachexieforschung, Medizinische Klinik mit Schwerpunkt für Kardiologie, Campus Virchow-Klinikum (CVK), Charité, Universitätsmedizin Berlin, Augustenburger Platz 1, D-13353 Berlin, Germany
2Clinical Cardiology, National Heart and Lung Institute, London, UK

* Corresponding author. Tel: +49 30 450 676 815; fax: +49 30 450 553 949. E-mail address: mathias.rauchhaus@charite.de

This editorial refers to ‘Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial’{dagger} by C.J. Malkin et al., on page 57

The first 10% of the full text of this article appears below.

Heart failure: therapeutic targets

Chronic heart failure (CHF) is a serious health care problem, associated with a high hospitalization rate and poor prognosis. CHF treatment means modern combination therapy, nevertheless, its associated mortality is higher than that of most cancers. Patients with CHF also have a poor quality-of-life.

The majority of today's therapeutic knowledge is based on evidence from large-scale multi-centre, double-blind, placebo-controlled intervention trials. During the last 20 years, a remarkable evolution of therapeutic concepts has taken place with ACE-inhibitors, beta-blockers, and aldosterone receptor antagonists marking milestones of CHF therapy.1 The therapeutic targets in patients with CHF are two-fold: first, an increase of life expectancy, and, secondly, improvements in quality-of-life.

First, prolongation of lifespan can be reached if the progression of the disease can be stopped, delayed, reversed, or if the risk for sudden cardiac death . . . [Full Text of this Article]

Testosterone replacement therapy and its implications

Heart failure and cancer: two completely different entities?


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial
Chris J. Malkin, Peter J. Pugh, John N. West, Edwin J.R. van Beek, T. Hugh Jones, and Kevin S. Channer
EHJ 2006 27: 57-64. [Abstract] [Full Text]  



This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
J. R. Bell, E. R. Porrello, C. E. Huggins, S. B. Harrap, and L. M. D. Delbridge
The intrinsic resistance of female hearts to an ischemic insult is abrogated in primary cardiac hypertrophy
Am J Physiol Heart Circ Physiol, April 1, 2008; 294(4): H1514 - H1522.
[Abstract] [Full Text] [PDF]